ICON Public (NASDAQ:ICLR) Coverage Initiated at Redburn Atlantic

Investment analysts at Redburn Atlantic initiated coverage on shares of ICON Public (NASDAQ:ICLR) in a research report issued to clients and investors on Monday, Marketbeat.com reports. The brokerage set a “neutral” rating and a $311.00 price target on the medical research company’s stock. Redburn Atlantic’s price objective would indicate a potential upside of 5.47% from the stock’s previous close.

A number of other research analysts have also commented on the company. Leerink Partnrs upgraded ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Barclays reduced their price objective on shares of ICON Public from $355.00 to $350.00 and set an “overweight” rating for the company in a report on Friday, July 26th. Leerink Partners assumed coverage on shares of ICON Public in a research report on Wednesday, September 18th. They issued an “outperform” rating and a $379.00 price target for the company. Robert W. Baird cut their price target on shares of ICON Public from $368.00 to $340.00 and set an “outperform” rating for the company in a research note on Friday, September 20th. Finally, StockNews.com lowered ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, ICON Public presently has a consensus rating of “Moderate Buy” and an average price target of $346.09.

ICON Public Price Performance

Shares of NASDAQ:ICLR opened at $294.87 on Monday. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 0.36. The business has a 50 day moving average price of $304.63 and a 200 day moving average price of $312.85. The company has a market cap of $24.33 billion, a price-to-earnings ratio of 35.87, a PEG ratio of 1.35 and a beta of 1.22. ICON Public has a twelve month low of $221.20 and a twelve month high of $347.72.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.68 by $0.07. The business had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.14 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. ICON Public’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the company posted $2.96 earnings per share. Research analysts predict that ICON Public will post 14.54 earnings per share for the current year.

Institutional Trading of ICON Public

Several large investors have recently made changes to their positions in the business. GAMMA Investing LLC grew its stake in shares of ICON Public by 22.5% during the first quarter. GAMMA Investing LLC now owns 174 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 32 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after buying an additional 42 shares during the last quarter. Motco increased its stake in shares of ICON Public by 1.5% in the 1st quarter. Motco now owns 3,882 shares of the medical research company’s stock valued at $1,304,000 after buying an additional 59 shares during the period. First National Bank of Hutchinson lifted its stake in shares of ICON Public by 5.7% during the first quarter. First National Bank of Hutchinson now owns 1,135 shares of the medical research company’s stock valued at $381,000 after acquiring an additional 61 shares during the period. Finally, Riverview Trust Co acquired a new position in shares of ICON Public during the first quarter valued at $31,000. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.